Samsung may have just sold more smartphones than Apple, according to industry scuttlebutt doing the rounds now--it's all based on rumor because Samsung doesn't reveal sales of its phones separately anymore, and the entire question is muddied because Apple sells just two versions of the iPhone and Samsung's stock covers hundreds of only slightly different varieties. Or, on the other hand, Samsung may not have beaten Apple. It may have achieved a greater marketshare of smartphones globally, or perhaps not. We really don't know, but the widespread chatter about it at least illustrates that people are watching this market keenly. We're more certain that Samsung has now ousted Nokia from its 14-year lead as biggest phone vendor--a plausible fact given Nokia's continuing slip from grace. And we're pretty convinced that Samsung's dirty tricks "smear" PR campaign against Apple customers--accusing them of being sheep--now rings completely hollow.
..................
..................
Lincoln, Nebraska, is an unlikely test bed for the future of journalism. It’s more than a thousand miles in both directions from the major coastal media markets. None of the country’s big magazine, newspaper, or broadcasting empires is headquartered here. Lincoln isn’t even particularly close to the companies that are producing the hardware of new media platforms. All the way out here on the Great Plains, however, Lincoln is a great place to practice flying drones.
“You can’t swing your arms in Manhattan without hitting people,” says Matt Waite, a journalism professor at the University of Nebraska in town. “Not a problem here. We’ve got space to stretch out and do things. And when you’re talking about flying a drone--especially when you’re first figuring it out--not having people around to crash into is a huge thing.”
Strange as this sounds, Waite is certain that drones will be a big part of the future of journalism. And the future of journalism will be tested here because there’s room to do it--quite literally--but also because the University of Nebraska is willing to do the R&D whereas media outlets and more staid journalism schools are not.
“There are not the very heady, haughty silos here,” says Gary Kebbel, the dean of Nebraska’s College of Journalism and Mass Communications. And he wants to enlist everyone from computer scientists to communications theorists to policy wonks working on the politics of drones. On this campus, that’s not such a strange suggestion. “There are people here who totally support and embody the mission of a land-grant university, which is to spread education throughout the state for the benefit of people in the state.”
Kebbel came here two years ago from the John S. and James L. Knight Foundation, where he ran the deep-pocketed Knight News Challenge. Kebbel lured Waite onto the faculty to join him last fall with the promise of doing, as Waite says, “out-there kind of stuff.” Waite, a Nebraska native, had previously helped develop the St. Petersburg Times’ political fact-checking site PolitiFact, the first website to ever win a Pulitzer Prize. Since arriving here from Miami, Kebbel has attracted attention for predicting that the future of media lies in mobile devices. He is currently planning to launch a Mobile Media Center that would begin to push the school (and the profession) in that direction.
“Mobile is the only device I’m aware of that is bridging all the digital divides I can possibly think of,” he says. And there are many: the divide between older and younger generations, between urban and rural, poor and wealthy, the well educated and the less so. Today, just about all of these groups have phones, if they have nothing else in common. And that means a journalist reporting on mobile devices can talk to anyone.
Kebbel is not, however, interested just in disseminating the news on cell phones (and this is good news for aspiring journalists who fear we’ll one day all be competing for the most Pulitzer-worthy text messages). He’s also talking about gathering the news with mobile devices. And this is where the drones come in. Kebbel wants the Mobile Media Center to attract grants and redistribute them to fund the research into drones and sensors and other portable tools that might revolutionize not just how the news is consumed, but how its acquired.
Journalists already mine stories from vast datasets. But that data typically comes from government sources. Waite and Kebbel want to deploy the types of mobile devices that could allow journalists to collect their own data. And they believe it’s the job of universities to figure out how to do this.
“They need to be doing R&D that, in particular, in these economic times, news organizations cannot do,” Kebbel says. “They don’t have the money. Some of the research that needs to be done, the boards of these companies would say 'you want to spend money on what?'"
Try to imagine the New York Times funding a drone R&D program. (OK, hologram-happy CNN is less of a stretch, but if they ever did light upon a good journalism drone, they probably wouldn’t share it with anyone.) To explain what Waite (pictured above on the right) wants to do with these things, it’s helpful to first think about weather (a perpetual top story in Nebraska). As a reporter, Waite chased tornados in Arkansas and covered hurricanes in Florida.
“I was thinking all along that it’s great we can rent a helicopter at a couple thousand dollars an hour,” he says, “but wouldn’t it be great to do this as a reporter with something on my back at the scene?” Like maybe a flying camera that could canvass a town in minutes?
Last summer, he stumbled on exactly such a drone at a digital-mapping conference. A company called Gatewing was demoing this video. In it, the Gatewing x100 flies overhead, snaps a zillion photos and then stitches them all back together into one georectified image. “I’m standing there watching this product demo,” Waite recalls, “and I’m thinking of every hurricane, tornado, every flood, every grass fire, every biblical disaster I’d ever covered as a reporter. And I’m like, 'here it is.'"
Waite tried to buy one on the spot. It turns out, though, that the Gatewing x100 costs about $65,000. And it’s currently illegal to fly it in the United States. Drones used for commercial purposes here are outlawed today. But the Federal Aviation Administration reauthorization bill passed by Congress earlier this year is supposed to change that. The FAA now has until September of 2015 to figure out how to legalize drones.
And that means that UNL has the next three years to scale up drone journalism--to develop both the physical drones themselves and the legal, ethical, and safety guidelines that will be needed to actually use them. Right now, Waite says, if you’ve got a drone with enough power to lift a serious camera off the ground, you are effectively launching a flying lawnmower into the air. And soon journalists want to deploy these things over protesting crowds and urban car wrecks?
So there is a lot of work to do out in Nebraska. And this is all just one piece of it.
“We’re defining mobile as broadly as we can, to not just think about it as an iPhone, an iPad, an Android,” Waite says. Today, he has a small drone prototype in his office, the kind of toy you can buy at any Brookstone store. “But with the drone I have, I can actually control the drone with a mobile device, I can record video from it, I can edit that video on my iPhone or iPad, and I can upload that all to the web and never touch a computer. That’s 'mobile' in a lot of senses."
And that’s before we even get to the conversation about which mobile devices people will be using to follow these stories.
Here is a new set of official statistics that can escalate the politically contentious debate on what constitutes the poverty line.
If average monthly consumption expenditure is taken as the benchmark of what an individual needs to survive, the poverty line would be Rs 66.10 for urban areas and Rs 35.10 for rural regions, while about 65% of the population will be below this cut-off.
The figures, based on the 66th round of the National Sample Survey for 2009-10, provide a more realistic marker for estimating both the poverty line and the population below it than the Planning Commission's calculation of Rs 28.65 per capita per day for cities and 22.42 for rural areas.
The rural and urban all-India averages for monthly expenditure are Rs 1,054 and Rs 1,984 per person, respectively, and if these are projected on the expenditure-population curve, the population below this works out to 64.47% (rural) and 66.70% (urban). Official sources said the exercise was carried out as part of a study and is based on NSSO data largely available in the public domain. While the government is revising its parameters, the monthly averages might be a useful means of estimating where to draw the poverty line.
With almost all states showing more than 60% of populations below the monthly expenditure averages, the oft-repeated claim that 70% of India lives on less than $2 a day has a ring of truth in it.
..................
If average monthly consumption expenditure is taken as the benchmark of what an individual needs to survive, the poverty line would be Rs 66.10 for urban areas and Rs 35.10 for rural regions, while about 65% of the population will be below this cut-off.
The figures, based on the 66th round of the National Sample Survey for 2009-10, provide a more realistic marker for estimating both the poverty line and the population below it than the Planning Commission's calculation of Rs 28.65 per capita per day for cities and 22.42 for rural areas.
The rural and urban all-India averages for monthly expenditure are Rs 1,054 and Rs 1,984 per person, respectively, and if these are projected on the expenditure-population curve, the population below this works out to 64.47% (rural) and 66.70% (urban). Official sources said the exercise was carried out as part of a study and is based on NSSO data largely available in the public domain. While the government is revising its parameters, the monthly averages might be a useful means of estimating where to draw the poverty line.
With almost all states showing more than 60% of populations below the monthly expenditure averages, the oft-repeated claim that 70% of India lives on less than $2 a day has a ring of truth in it.
..................
The Food and Drug Administration on Friday approved a new impotence drug, Vivus Inc.'s Stendra.
The pill is intended to be taken 30 minutes before sex, but Vivus said that in clinical trials, some patients were able to have sex as little as 15 minutes after taking the drug. Pfizer Inc.'s Viagra is supposed to be taken at least 30 minutes before sex. The FDA said an estimated 30 million men have importance, or erectile dysfunction.
In clinical trials, the most common side effects of Stendra, or avanafil, were headache, redness of the face and other areas, nasal congestion, back pain, and symptoms similar to the common cold. Vivus said the drug shouldn't be taken more than once per day.
Vivus licensed Stendra from Japanese drugmaker Mitsubishi Tanabe Pharma. It has worldwide rights to the drug except for some countries in the Asia-Pacific region.
Vivus has said it is talking to potential marketing partners for Stendra, and may sell the drug outright to another company. Analysts said Friday they expect Vivus to sell Stendra to another drug company to help fund future sales of its experimental obesity drug Qnexa.
"Given the large market opportunity and the potentially differentiating faster onset of action, we believe that in the hands of big pharma Stendra is probably worth around $300 million," said Cowen and Co. analyst Simos Simeonidis.
Simeonidis said Vivus will need a partner to help sell Qnexa, and will turn to a large pharmaceutical company with experience launching major drugs. He said it's also possible that another company could buy Vivus.
Rodman and Renshaw analyst Michael King said Vivus could get as much as $100 million for the rights to Stendra. He estimated that U.S. sales could peak at $483 million in 2016. After that, he said sales are likely to fall because generic versions of Viagra and other drugs will reach the market.
Vivus is based in Mountain View, Calif. The FDA was scheduled to make a decision on Qnexa this month, but announced it is extending its review by another three months. It is now expected to make a ruling by July 17.
Shares of Vivus ended the session up 72 cents, or 3 percent, at $25.15. After-hours the stock picked up 40 cents to $25.55
The pill is intended to be taken 30 minutes before sex, but Vivus said that in clinical trials, some patients were able to have sex as little as 15 minutes after taking the drug. Pfizer Inc.'s Viagra is supposed to be taken at least 30 minutes before sex. The FDA said an estimated 30 million men have importance, or erectile dysfunction.
Vivus licensed Stendra from Japanese drugmaker Mitsubishi Tanabe Pharma. It has worldwide rights to the drug except for some countries in the Asia-Pacific region.
Vivus has said it is talking to potential marketing partners for Stendra, and may sell the drug outright to another company. Analysts said Friday they expect Vivus to sell Stendra to another drug company to help fund future sales of its experimental obesity drug Qnexa.
"Given the large market opportunity and the potentially differentiating faster onset of action, we believe that in the hands of big pharma Stendra is probably worth around $300 million," said Cowen and Co. analyst Simos Simeonidis.
Simeonidis said Vivus will need a partner to help sell Qnexa, and will turn to a large pharmaceutical company with experience launching major drugs. He said it's also possible that another company could buy Vivus.
Rodman and Renshaw analyst Michael King said Vivus could get as much as $100 million for the rights to Stendra. He estimated that U.S. sales could peak at $483 million in 2016. After that, he said sales are likely to fall because generic versions of Viagra and other drugs will reach the market.
Vivus is based in Mountain View, Calif. The FDA was scheduled to make a decision on Qnexa this month, but announced it is extending its review by another three months. It is now expected to make a ruling by July 17.
Shares of Vivus ended the session up 72 cents, or 3 percent, at $25.15. After-hours the stock picked up 40 cents to $25.55
A few weeks ago, I returned from a week-long technology-free vacation with my family. No computer, no phone, no email.
When I got to the office and checked my computer, I had hundreds of email messages waiting for me. I took a deep breath and started in on them. Three hours later, my inbox — a week's worth of messages — was empty.
Contrast that with my experience the next day, and each day after that, when I've spent well more than three hours each day on email. Some of that time involved back-and-forth emailing, but still, the difference is dramatic.
I've come to the conclusion that I use email to distract myself. Whenever I feel the least bit uneasy, I check my email. Stuck while writing an article? Bored on a phone call? Standing in an elevator, frustrated in a meeting, anxious about an interaction? Might as well check email. It's an ever-present, easy-access way to avoid my feelings of discomfort.
What makes it so compelling is that it's so compelling. I wonder what's waiting for me in my inbox? It's scintillating.
It also feels legitimate, even responsible. I'm working. I need to make sure I don't miss an important message or fail to respond in a timely fashion.
But it's become a serious problem. When we don't control our email habit, we are controlled by it. Everyone I know complains about email overload.
Email pours in, with no break to its flow. And like addicts, we check it incessantly, drawing ourselves away from meetings, conversations, personal time, or whatever is right in front of us.
But it's not just the abundance of email that's our problem — it's the inefficiency in how we deal with it. Each time we check our email on the fly, we lose time pulling out our phones, loading the email, reading new emails without taking action on them, and re-reading those to which we haven't yet responded. Then, back at our computers, we re-read them again.
It's rattling us. According to USA Today the number of lawsuits filed by employees claiming unfair overtime is up 32% since 2008. The major reason for the increase? Email on devices like smartphones is intruding on our personal time.
The solution, I believe, is hidden in my post-vacation email experience.
Instead of checking email continuously and from multiple devices, schedule specific email time during the day while you are at your computer. All other time is email vacation time.
We are most efficient when we answer email in bulk at our computers. We move faster, can access files when we need them, and link more quickly and easily to other programs like our calendars. Also, when we sit down for the express purpose of doing emails, we have our email heads on. We are more focused, more driven, wasting no time in transition from one activity to another.
I bulk process my email three times a day in 30-minute increments, once in the morning, once mid-day, and once before shutting down my computer for the day. I use a timer and when it beeps, I close my email program.
Outside my designated email times I don't access my email — from any device — until my next scheduled email session. I no longer use my phone for email unless I'm away from my computer all day.
When the urge to check arises — and it arises often — I take a deep breath and feel whatever feelings come up. And then I focus on whatever I'm doing, even if what I'm doing is waiting. I let my mind relax.
Here's what I've found: I don't miss a thing.
In fact, it's the opposite. I gain presence throughout my day. I am focused on what's around me in the moment, without distraction. I listen more attentively, notice people's subtle reactions I would otherwise overlook, and come up with more ideas as my mind wanders. I'm more productive, more sensitive, more creative, and happier.
I'm also going through my email faster and with more attention than before. I don't make those I'm-moving-too-fast mistakes like copying the wrong person or sending an email before finishing it or saying something hurtful. So I'm also more efficient.
But what if someone needs an immediate response? Worrying about that is precisely the kind of misguided rationalization that reinforces our addiction. I haven't angered anyone with my new process. In fact, I don't think anyone has noticed my mini email vacations because responding to an email within a few hours is perfectly reasonable. And, in the off chance that they need a response within minutes, they'll find another way to reach me, either by texting or calling.
Email is no longer an overwhelming burden to me. I'm spending an hour and a half a day on it, which for me is the right amount. You may need more or less time per day. Experiment and then schedule the appropriate time slots.
The hardest part is resisting the temptation to check during your off-email hours. My advice? When you have the urge to check your email, check yourself instead. What's going on for you? What are you feeling? Take a deep breath and relax into an undistracted moment.
For a brief moment in the middle of a hectic workday, it just might feel like you're on vacation.
View full article on the link
The Asia-Pacific Sovereign Seesaw: If Oil Prices Soar, Some Ratings Could Fall
Tensions in the Middle East are likely to keep oil prices elevated in the near future despite recent declines. Most observers don't expect the U.S.-Iran standoff to escalate into conflict. Even so, it has already begun to hurt economically. A widely expected weak year for economic growth now has the potential to worsen. A further large increase in crude oil prices would adversely affect most Asia-Pacific economies. If prices stay above US$150 for more than a year, some sovereigns in the region could be downgraded.
• Novo Nordisk A/S (NVO) to Boost US Workforce by 15 Percent More...
• Imprimis Pharmaceuticals Closes $7.95 Million Financing and Provides Progress Report to Shareholders More...
• Jazz Pharmaceuticals, Inc. (JAZZ) Buying EUSA Pharma for Up to $700 Million More...
• Renhe Pharmacy Pays $46 Million for Two Pharma Acquisitions More...
• Allenex AB Sells Its Holding in Pharmacolog More...
• VWR International, Inc. Signs Agreement to Acquire basan Germany GmbH More...
• FAES Farma and Invida (a Menarini Group Company) Announce Agreement to Commercialize Bilastine in 17 Markets in Asia - Pacific More...
• Somaxon Pharmaceuticals, Inc. (SOMX) and CJ CheilJedang Announce Silenor® Collaboration in South Korea More...
• Array BioPharma, Inc. (ARRY) Names Ron Squarer Chief Executive Officer More...
• Trinean nv Appoints New CEO and Secures 2.7 Million Euro Financing More...
• PDL BioPharma, Inc. (PDLI) Appoints Bruce Tomlinsonas Chief Financial Officer More...
• Ms. Julia R. Brown and Mr. Davey S. Scoon Join Biodel Inc. (BIOD) Board of Directors More...
• Lota S. Zoth Joins Orexigen Therapeutics, Inc. (OREX) Board of Directors More...
• Alnylam Pharmaceuticals (ALNY) to Webcast Conference Call Discussing First Quarter 2012 Financial Results More...
• Accelrys Inc. (ACCL) to Announce First Quarter 2012 Results on May 3, 2012 More...
• First Quarter 2012/Annual Meeting: BASF With Solid Start to the Year More...
• BioMarin Pharmaceutical Inc. (BMRN) Announces First Quarter 2012 Financial Results More...
• BioScrip (BIOS) to Host First Quarter 2012 Earnings Call More...
• Could Bristol-Myers Squibb Company (BMY) be a Target of Bribery? More...
• Sucampo Pharmaceuticals, Inc. Provides Update on Anticipated Arbitration Decision Date More...
• FDA Rejects Amgen (AMGN)'s BLA for Xgeva More...
• GlaxoSmithKline (GSK) and Genmab A/S (GEN.CO) Release: New Drug Application for Arzerra Submitted in Japan More...
• FDA Warns Not to Mix Merck & Co., Inc. (MRK) Hep C Drug With HIV Meds More...
• FDA Approves Novartis AG (NVS)'s Afinitor for Kidney Tumors More...
• FDA Approves GlaxoSmithKline (GSK)'s Votrient® for Deadly Sarcomas More...
• Results From Chelsea Therapeutics, Inc. (CHTP)' Pivotal Northera™ (Droxidopa) Study to be Presented at the American Academy of Neurology's Annual Meeting More...
• Baxter International, Inc. (BAX) Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Neuropathy at American Academy of Neurology Annual Meeting More...
• UCB, Inc. (UCBJF.PK) Release: Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology More...
• New Tysabri Data Presented at 64th Annual American Academy of Neurology Meeting Highlight Biogen Idec, Inc. (Massachusetts) (BIIB) & Biogen Idec, Inc. (Massachusetts) (BIIB) Commitment to Improving Outcomes in Multiple Sclerosis More...
• Building Muscle Without Heavy Weights, McMaster University Study More...
• Analytic Thinking Can Decrease Religious Belief, University of British Columbia Study More...
• Women Who Smoke in Pregnancy More Likely to Have Child With High Functioning Autism, University of Wisconsin Study More...
• High Salt Intake Linked to Higher Stroke Risk, University of Warwick Study More...
• Breast Cancer Link With Diet, Karolinska Institute Study More...
• Ampio Pharmaceuticals, Inc. (AMPE) Awarded US and Canadian Patents That Will Bolster the Commercialization of Optina™ for the Treatment of Diabetic Macular Edema (DME) More...
• Ranbaxy Laboratories (RANBAXY.BO) Creates India's First New Drug More...
• Pharmaxis Ltd (PXS.AX) Receives Approval to Market Bronchitol in the EU More...
• GlaxoSmithKline (GSK) Attacks National Institute for Clinical Excellence (NICE) for Rejecting New Lupus Treatment More...
• Imprimis Pharmaceuticals Closes $7.95 Million Financing and Provides Progress Report to Shareholders More...
• Jazz Pharmaceuticals, Inc. (JAZZ) Buying EUSA Pharma for Up to $700 Million More...
• Renhe Pharmacy Pays $46 Million for Two Pharma Acquisitions More...
• Allenex AB Sells Its Holding in Pharmacolog More...
• VWR International, Inc. Signs Agreement to Acquire basan Germany GmbH More...
• FAES Farma and Invida (a Menarini Group Company) Announce Agreement to Commercialize Bilastine in 17 Markets in Asia - Pacific More...
• Somaxon Pharmaceuticals, Inc. (SOMX) and CJ CheilJedang Announce Silenor® Collaboration in South Korea More...
• Array BioPharma, Inc. (ARRY) Names Ron Squarer Chief Executive Officer More...
• Trinean nv Appoints New CEO and Secures 2.7 Million Euro Financing More...
• PDL BioPharma, Inc. (PDLI) Appoints Bruce Tomlinsonas Chief Financial Officer More...
• Ms. Julia R. Brown and Mr. Davey S. Scoon Join Biodel Inc. (BIOD) Board of Directors More...
• Lota S. Zoth Joins Orexigen Therapeutics, Inc. (OREX) Board of Directors More...
• Alnylam Pharmaceuticals (ALNY) to Webcast Conference Call Discussing First Quarter 2012 Financial Results More...
• Accelrys Inc. (ACCL) to Announce First Quarter 2012 Results on May 3, 2012 More...
• First Quarter 2012/Annual Meeting: BASF With Solid Start to the Year More...
• BioMarin Pharmaceutical Inc. (BMRN) Announces First Quarter 2012 Financial Results More...
• BioScrip (BIOS) to Host First Quarter 2012 Earnings Call More...
• Could Bristol-Myers Squibb Company (BMY) be a Target of Bribery? More...
• Sucampo Pharmaceuticals, Inc. Provides Update on Anticipated Arbitration Decision Date More...
• FDA Rejects Amgen (AMGN)'s BLA for Xgeva More...
• GlaxoSmithKline (GSK) and Genmab A/S (GEN.CO) Release: New Drug Application for Arzerra Submitted in Japan More...
• FDA Warns Not to Mix Merck & Co., Inc. (MRK) Hep C Drug With HIV Meds More...
• FDA Approves Novartis AG (NVS)'s Afinitor for Kidney Tumors More...
• FDA Approves GlaxoSmithKline (GSK)'s Votrient® for Deadly Sarcomas More...
• Results From Chelsea Therapeutics, Inc. (CHTP)' Pivotal Northera™ (Droxidopa) Study to be Presented at the American Academy of Neurology's Annual Meeting More...
• Baxter International, Inc. (BAX) Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Neuropathy at American Academy of Neurology Annual Meeting More...
• UCB, Inc. (UCBJF.PK) Release: Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology More...
• New Tysabri Data Presented at 64th Annual American Academy of Neurology Meeting Highlight Biogen Idec, Inc. (Massachusetts) (BIIB) & Biogen Idec, Inc. (Massachusetts) (BIIB) Commitment to Improving Outcomes in Multiple Sclerosis More...
• Building Muscle Without Heavy Weights, McMaster University Study More...
• Analytic Thinking Can Decrease Religious Belief, University of British Columbia Study More...
• Women Who Smoke in Pregnancy More Likely to Have Child With High Functioning Autism, University of Wisconsin Study More...
• High Salt Intake Linked to Higher Stroke Risk, University of Warwick Study More...
• Breast Cancer Link With Diet, Karolinska Institute Study More...
• Ampio Pharmaceuticals, Inc. (AMPE) Awarded US and Canadian Patents That Will Bolster the Commercialization of Optina™ for the Treatment of Diabetic Macular Edema (DME) More...
• Ranbaxy Laboratories (RANBAXY.BO) Creates India's First New Drug More...
• Pharmaxis Ltd (PXS.AX) Receives Approval to Market Bronchitol in the EU More...
• GlaxoSmithKline (GSK) Attacks National Institute for Clinical Excellence (NICE) for Rejecting New Lupus Treatment More...
• AstraZeneca PLC (AZN) CEO Steps Down More...
• Rempex Pharmaceuticals Appoints Jennifer Cayer New Chief Operating Officer More...
• Albany Molecular Research, Inc. (AMRI) (AMRI) Hires Director of In Vitro Biology in Singapore More...
• BioNeutral Appoints New Board of Directors Member and Seeks to Expand Its Management Team More...
• Valence Life Sciences Announces Promotion of Scott Morenstein and Hiring of Robert Ferraioli More...
• Amgen (AMGN) to Create 100 Jobs More...
• Johnson & Johnson (JNJ) CEO Gorsky Says Company Will Grow While Rivals Shrink More...
• Galena Biopharma (RXII) Takes Final Actions to Complete Spin-Off of RXi Pharmaceuticals (RXII) More...
• Galenea to Receive $6 Million From The Stanley Medical Research Instituteto Progress Pro-Cognitive Drug Discovery and Development Program More...
• Watson Pharmaceuticals, Inc. (WPI)'s $5.9 Billion for Actavis Earning Applause as Shares Pop More...
• Onyx Pharmaceuticals, Inc. (ONXX) Shares Rally Late Afternoon Amid Rumor of Bayer AG (BAY.F) Acquisition More...
• Baxter International, Inc. (BAX) Completes Purchase of SIGMA International More...
• Epizyme Gets $90 Million in Epigenetics Partnership With Celgene Corporation (CELG) More...
• Southern Research Institute Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings More...
• Evotec AG (EVTG.F) and Active Biotech AB (BTPC) Extend and Expand Medicinal Chemistry Collaboration More...
• Zalicus Inc. (ZLCS) Provides Oncology Research Collaboration Update More...
• Hi-Tech Pharmacal (HITK) Licenses Rights to Lidocaine 5% Ointment More...
• Active Biotech AB (BTPC) Interim Report January - March 2012 More...
• AVEO Pharmaceuticals, Inc. (AVEO) Announces Timing for First Quarter Financial Results, Webcast and Conference Call More...
• Alimera Sciences (ALIM) to Release First Quarter Fiscal Year 2012 Financial Results More...
• Acorda Therapeutics (ACOR) to Host Conference Call to Discuss First Quarter 2012 Financial Results on May 3, 2012 More...
• AmerisourceBergen Corporation (ABC) Reports $0.81 in Diluted EPS for the March Quarter More...
• Icahn Drops Suit After Making Nice With Amylin Pharmaceuticals, Inc. (AMLN) CEO More...
• Mylan Inc. (MYL) and Pfizer Inc. (PFE) Announce Epinephrine Auto-injector Settlement Agreement With Teva Pharmaceutical Industries Limited (TEVA) More...
• Takeda Pharmaceutical Co. Ltd. (TKDG.DE)'s Actos Successor Fails to Win FDA OK More...
• Repligen Corporation (RGEN) Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting More...
• Onyx Pharmaceuticals, Inc. (ONXX) Says FDA's ODAC Will Review NDA For Carfilzomib More...
• Pfizer Inc. (PFE) Drug Reduced Autism Signs in Mice More...
• Forest Laboratories, Inc. (FRX) and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients With Major Depressive Disorder More...
• Shire plc (SHPGY) Reports Positive Phase 2 Study Met Primary End Point for Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) in Adults With Binge Eating Disorder More...
• Omthera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Phase 3 EVOLVE Study More...
• Banner Sun Health Research Institute Release: Study Findings Confirming Reliable Beta-Amyloid Imaging in the Living Brain Presented at American Academy of Neurology Annual Meeting in New Orleans More...
• Eating More Berries May Delay Memory Decline, Harvard Medical School Study More...
• Poor Sleep Heightens "Ringing Ear" Disease Symptoms, Henry Ford Health System Study More...
• Leafy Greens Help Prevent Damage Caused by a Workout, Edinburgh Napier University Study More...
• Switching Subject Categories Could Improve Test Scores, Syracuse University Study More...
• Feel-Good Music Helps With Psychological Counseling, Concordia University Study More...
• Apricus Biosciences (APRI) Receives Notice of Issuance for First Prevonco™ Patent in the United States More...
• Bio Scientific Corporation Introduces Optimized Directional RNA-Seq Kits With Innovative Bias Reducing Technology More...
• Tianyin Pharmaceutical Co, Inc. Provides Progress Updates on its GMOL Flagship Product More...
• Watson Pharmaceuticals, Inc. (WPI) and Antares Pharma, Inc. (AIS) Announce the Introduction of Gelnique™, for the Treatment of Overactive Bladder More...
• Rempex Pharmaceuticals Appoints Jennifer Cayer New Chief Operating Officer More...
• Albany Molecular Research, Inc. (AMRI) (AMRI) Hires Director of In Vitro Biology in Singapore More...
• BioNeutral Appoints New Board of Directors Member and Seeks to Expand Its Management Team More...
• Valence Life Sciences Announces Promotion of Scott Morenstein and Hiring of Robert Ferraioli More...
• Amgen (AMGN) to Create 100 Jobs More...
• Johnson & Johnson (JNJ) CEO Gorsky Says Company Will Grow While Rivals Shrink More...
• Galena Biopharma (RXII) Takes Final Actions to Complete Spin-Off of RXi Pharmaceuticals (RXII) More...
• Galenea to Receive $6 Million From The Stanley Medical Research Instituteto Progress Pro-Cognitive Drug Discovery and Development Program More...
• Watson Pharmaceuticals, Inc. (WPI)'s $5.9 Billion for Actavis Earning Applause as Shares Pop More...
• Onyx Pharmaceuticals, Inc. (ONXX) Shares Rally Late Afternoon Amid Rumor of Bayer AG (BAY.F) Acquisition More...
• Baxter International, Inc. (BAX) Completes Purchase of SIGMA International More...
• Epizyme Gets $90 Million in Epigenetics Partnership With Celgene Corporation (CELG) More...
• Southern Research Institute Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings More...
• Evotec AG (EVTG.F) and Active Biotech AB (BTPC) Extend and Expand Medicinal Chemistry Collaboration More...
• Zalicus Inc. (ZLCS) Provides Oncology Research Collaboration Update More...
• Hi-Tech Pharmacal (HITK) Licenses Rights to Lidocaine 5% Ointment More...
• Active Biotech AB (BTPC) Interim Report January - March 2012 More...
• AVEO Pharmaceuticals, Inc. (AVEO) Announces Timing for First Quarter Financial Results, Webcast and Conference Call More...
• Alimera Sciences (ALIM) to Release First Quarter Fiscal Year 2012 Financial Results More...
• Acorda Therapeutics (ACOR) to Host Conference Call to Discuss First Quarter 2012 Financial Results on May 3, 2012 More...
• AmerisourceBergen Corporation (ABC) Reports $0.81 in Diluted EPS for the March Quarter More...
• Icahn Drops Suit After Making Nice With Amylin Pharmaceuticals, Inc. (AMLN) CEO More...
• Mylan Inc. (MYL) and Pfizer Inc. (PFE) Announce Epinephrine Auto-injector Settlement Agreement With Teva Pharmaceutical Industries Limited (TEVA) More...
• Takeda Pharmaceutical Co. Ltd. (TKDG.DE)'s Actos Successor Fails to Win FDA OK More...
• Repligen Corporation (RGEN) Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting More...
• Onyx Pharmaceuticals, Inc. (ONXX) Says FDA's ODAC Will Review NDA For Carfilzomib More...
• Pfizer Inc. (PFE) Drug Reduced Autism Signs in Mice More...
• Forest Laboratories, Inc. (FRX) and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients With Major Depressive Disorder More...
• Shire plc (SHPGY) Reports Positive Phase 2 Study Met Primary End Point for Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) in Adults With Binge Eating Disorder More...
• Omthera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Phase 3 EVOLVE Study More...
• Banner Sun Health Research Institute Release: Study Findings Confirming Reliable Beta-Amyloid Imaging in the Living Brain Presented at American Academy of Neurology Annual Meeting in New Orleans More...
• Eating More Berries May Delay Memory Decline, Harvard Medical School Study More...
• Poor Sleep Heightens "Ringing Ear" Disease Symptoms, Henry Ford Health System Study More...
• Leafy Greens Help Prevent Damage Caused by a Workout, Edinburgh Napier University Study More...
• Switching Subject Categories Could Improve Test Scores, Syracuse University Study More...
• Feel-Good Music Helps With Psychological Counseling, Concordia University Study More...
• Apricus Biosciences (APRI) Receives Notice of Issuance for First Prevonco™ Patent in the United States More...
• Bio Scientific Corporation Introduces Optimized Directional RNA-Seq Kits With Innovative Bias Reducing Technology More...
• Tianyin Pharmaceutical Co, Inc. Provides Progress Updates on its GMOL Flagship Product More...
• Watson Pharmaceuticals, Inc. (WPI) and Antares Pharma, Inc. (AIS) Announce the Introduction of Gelnique™, for the Treatment of Overactive Bladder More...
In the era of digital payment systems, technology firms are competing to work out an easy electronic approach for payments. Walmart, the giant has work out the way to pay cash while shopping online. Customers who don't have credit cards or bank accounts may find it easier to pay cash of their online purchases at walmart.com
Walmart has set up a system to allow online shoppers to pay with cash. Pay With Cash allows customers without credit cards to choose from Walmart.com's extended catalogue of items, and pay for their purchase at a nearby store. Their order then ships. It's geared towards customers without bank accounts or insufficient electronic banking access--those who "rely on cash transactions, as well as those who are wary of using credit cards online," Walmart explains in a release. Walmart built the system in-house, Walmart.com CEO Joel Anderson told AllThingsD. That's a strategy that online stores employ in other parts of the world like India and China, where a chunk of the population is underbanked, and where customers are still wary of using cards online and prefer to pay for purchases after inspecting them in real life.
Walmart has set up a system to allow online shoppers to pay with cash. Pay With Cash allows customers without credit cards to choose from Walmart.com's extended catalogue of items, and pay for their purchase at a nearby store. Their order then ships. It's geared towards customers without bank accounts or insufficient electronic banking access--those who "rely on cash transactions, as well as those who are wary of using credit cards online," Walmart explains in a release. Walmart built the system in-house, Walmart.com CEO Joel Anderson told AllThingsD. That's a strategy that online stores employ in other parts of the world like India and China, where a chunk of the population is underbanked, and where customers are still wary of using cards online and prefer to pay for purchases after inspecting them in real life.
Below is the list of 50+ Strong Action Verbs You Need to Use on Your Resume Now
By Jessica Holbrook Hernandez, Expert Resume WriterStop using passive terms on your resume; passive terms dilute the quality and value of what you offer the employer. Seriously, if you’re using any of the following terminology, you need to make a change today!
Demonstrated mastery of...Responsibility for...Duties included...Worked with...Familiar with...Knowledge of (or) Knowledgeable in...
These passive terms are not action-oriented, and they make for a rather lackluster resume. Instead, show the employer exactly what you’re capable of achieving and bringing to the table! Below you’ll find a list of 50+ strong action verbs that you can put on your resume NOW to spice things up!
|
